Published in Health Econ on December 28, 2010
Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet (2014) 2.54
Direct-to-consumer genomics on the scales of autonomy. J Med Ethics (2014) 1.47
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Concepts of 'personalization' in personalized medicine: implications for economic evaluation. Pharmacoeconomics (2015) 1.16
Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarkers (2011) 1.06
How much diagnostic safety can we afford, and how should we decide? A health economics perspective. BMJ Qual Saf (2013) 1.06
A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol (2013) 1.03
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimers Dement (2015) 1.03
Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. Prog Neurobiol (2013) 0.98
Hepatitis C screening: getting it right. Hepatology (2012) 0.94
Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc (2014) 0.93
Emerging issues in public health genomics. Annu Rev Genomics Hum Genet (2014) 0.91
Direct-to-consumer testing: if consumers are not anxious, why are policymakers? Hum Genet (2011) 0.91
Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. Alzheimers Res Ther (2013) 0.89
"Is it really worth it to get tested?": primary care patients' impressions of predictive SNP testing for colon cancer. J Genet Couns (2012) 0.87
Public beliefs and knowledge about risk and protective factors for Alzheimer's disease. Alzheimers Dement (2014) 0.86
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. Neurodegener Dis Manag (2015) 0.84
Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening. Value Health (2014) 0.79
Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics. Neurol Clin (2016) 0.78
Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps. Int J Alzheimers Dis (2012) 0.77
Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. Neurobiol Aging (2015) 0.77
Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results. JAMA Neurol (2015) 0.76
Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine. Value Health (2017) 0.75
Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study. Alzheimers Res Ther (2016) 0.75
Why do we pay for information that we won't use? A cognitive-based explanation for genetic information seeking. Eur J Hum Genet (2015) 0.75
Willingness to pay for genetic testing for inherited retinal disease. Eur J Hum Genet (2014) 0.75
Using willingness-to-pay to establish patient preferences for cancer testing in primary care. BMC Med Inform Decis Mak (2016) 0.75
The price of whole-genome sequencing may be decreasing, but who will be sequenced? Per Med (2017) 0.75
Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke (2009) 4.14
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med (2015) 3.75
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Associations of gestational weight gain with short- and longer-term maternal and child health outcomes. Am J Epidemiol (2009) 3.02
Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet (2009) 2.81
Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol (2008) 2.77
Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging (2013) 2.56
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
A quantitative analysis of fish consumption and coronary heart disease mortality. Am J Prev Med (2005) 2.27
Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA (2011) 2.27
Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol (2006) 2.27
Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. Circulation (2012) 2.24
Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood) (2010) 2.08
Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis (2011) 2.01
Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol (2010) 1.93
Measuring the Value of Prescription Drugs. N Engl J Med (2015) 1.91
Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. Stroke (2006) 1.86
Predicting nursing home admission: estimates from a 7-year follow-up of a nationally representative sample of older Americans. Alzheimer Dis Assoc Disord (2004) 1.85
Potentially large yet uncertain benefits: a meta-analysis of patent foramen ovale closure trials. Stroke (2013) 1.81
Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke (2011) 1.74
Elapsed time in emergency medical services for patients with cardiac complaints: are some patients at greater risk for delay? Circ Cardiovasc Qual Outcomes (2009) 1.71
Evidence of systematic duplication by new percutaneous coronary intervention programs. Circ Cardiovasc Qual Outcomes (2013) 1.66
Still no closure on the question of PFO closure. N Engl J Med (2013) 1.64
Heterogeneity of the phenotypic definition of coronary artery disease and its impact on genetic association studies. Circ Cardiovasc Genet (2010) 1.62
Effectiveness and Implications of Alternative Placebo Treatments: A Systematic Review and Network Meta-analysis of Osteoarthritis Trials. Ann Intern Med (2015) 1.61
Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood) (2005) 1.57
Personalised medicine: not just in our genes. BMJ (2012) 1.51
Selecting human health metrics for environmental decision-support tools. Risk Anal (2002) 1.51
Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke (2006) 1.47
Fuels for urban transit buses: a cost-effectiveness analysis. Environ Sci Technol (2003) 1.45
Flexible epidemiological model for estimates and short-term projections in generalised HIV/AIDS epidemics. Sex Transm Infect (2010) 1.44
Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann Intern Med (2009) 1.40
A quantitative analysis of fish consumption and stroke risk. Am J Prev Med (2005) 1.39
Evidence-based medicine and the hard problem of multimorbidity. J Gen Intern Med (2014) 1.34
Risk prediction models for patients with chronic kidney disease: a systematic review. Ann Intern Med (2013) 1.33
The risk of paradoxical embolism (RoPE) study: initial description of the completed database. Int J Stroke (2012) 1.32
Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working group. Circulation (2011) 1.30
A systematic review of the evidence concerning the economic impact of employee-focused health promotion and wellness programs. J Occup Environ Med (2013) 1.30
Comparative effectiveness of ST-segment-elevation myocardial infarction regionalization strategies. Circ Cardiovasc Qual Outcomes (2010) 1.28
Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol (2002) 1.26
National HIV prevalence estimates for sub-Saharan Africa: controlling selection bias with Heckman-type selection models. Sex Transm Infect (2012) 1.26
Economic evaluation of the US Environmental Protection Agency's SunWise program: sun protection education for young children. Pediatrics (2008) 1.23
Stroke--an equal opportunity for the initiation of statin therapy. N Engl J Med (2006) 1.22
Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations. Pharmacoeconomics (2007) 1.22
A CTSA agenda to advance methods for comparative effectiveness research. Clin Transl Sci (2011) 1.21
Safety impacts of SUVs, vans, and pickup trucks in two-vehicle crashes. Risk Anal (2003) 1.18
Multimorbidity and evidence generation. J Gen Intern Med (2014) 1.17
Effect of the Fukushima nuclear accident on the risk perception of residents near a nuclear power plant in China. Proc Natl Acad Sci U S A (2013) 1.14
Random treatment assignment using mathematical equipoise for comparative effectiveness trials. Clin Transl Sci (2011) 1.14
Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease. Health Aff (Millwood) (2014) 1.13
The empirical basis for determinations of medical futility. J Gen Intern Med (2010) 1.13
Valuation of the risk of SARS in Taiwan. Health Econ (2005) 1.12
When is evidence sufficient? Health Aff (Millwood) (2005) 1.12
30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics (2009) 1.12
Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol (2012) 1.08
Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes (2014) 1.07
Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy. Clin Infect Dis (2013) 1.06
Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Heart Rhythm (2008) 1.05
Benchmarks and determinants of adherence to stroke performance measures. Stroke (2008) 1.04
Toward modernizing the systematic review pipeline in genetics: efficient updating via data mining. Genet Med (2012) 1.04
Health trade-offs from policies to alter fish consumption. Am J Prev Med (2005) 1.04
Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis. Pediatrics (2012) 1.02
Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum (2009) 1.01
Comparison of mortality benefit of immediate thrombolytic therapy versus delayed primary angioplasty for acute myocardial infarction. Am J Cardiol (2007) 1.01
Patent foramen ovale and cryptogenic stroke. N Engl J Med (2008) 1.00
Timing of prophylactic surgery in prevention of diverticulitis recurrence: a cost-effectiveness analysis. Dig Dis Sci (2002) 0.99
The influence of geographic location on population exposure to emissions from power plants throughout China. Environ Int (2005) 0.98
6 EZ steps to improving your performance: (or how to make P4P pay 4U!). JAMA (2008) 0.98
A geospatial analysis of emergency transport and inter-hospital transfer in ST-segment elevation myocardial infarction. Am J Cardiol (2007) 0.97
How to integrate multiple comorbidities in guideline development: article 10 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc (2012) 0.97
Are unadjusted analyses of clinical trials inappropriately biased toward the null? Stroke (2009) 0.95
Assessing preferences for prevention versus treatment using willingness to pay. Med Decis Making (2002) 0.95
Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease. Am Heart J (2011) 0.95
Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. Alzheimers Dement (2012) 0.94
Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis. Genet Med (2010) 0.94
Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis (2013) 0.94
The Surgical Apgar Score in hip and knee arthroplasty. Clin Orthop Relat Res (2010) 0.94
Cost savings and cost-effectiveness of clinical preventive care. Synth Proj Res Synth Rep (2009) 0.91
Cardiac screening prior to stimulant treatment of ADHD: a survey of US-based pediatricians. Pediatrics (2012) 0.90
Aggregating and disaggregating patients in clinical trials and their subgroup analyses. Ann Intern Med (2010) 0.90
Controversies in cardioembolic stroke. Curr Treat Options Cardiovasc Med (2015) 0.90
Reexamining the emperor's new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder. Circ Cardiovasc Qual Outcomes (2008) 0.90
A clinical and economic evaluation of enteral nutrition. Curr Med Res Opin (2010) 0.89
A percutaneous coronary intervention-thrombolytic predictive instrument to assist choosing between immediate thrombolytic therapy versus delayed primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol (2008) 0.89
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders. Alzheimers Dement (2013) 0.88
Tools for comparative analysis of alternatives: competing or complementary perspectives? Risk Anal (2002) 0.88
Willingness to pay for weight-control treatment. Health Policy (2009) 0.87
Dissemination and implementation of comparative effectiveness evidence: key informant interviews with Clinical and Translational Science Award institutions. J Comp Eff Res (2013) 0.87
Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures. Value Health (2013) 0.86
A probabilistic characterization of the health benefits of reducing methyl mercury intake in the United States. Environ Sci Technol (2010) 0.85
Parental age difference, educationally assortative mating and offspring count: evidence from a contemporary population in Taiwan. Biol Lett (2011) 0.85
Tiered chemical testing: a value of information approach. Risk Anal (2004) 0.85
25-hydroxyvitamin D levels and juvenile idiopathic arthritis: is there an association with disease activity? Rheumatol Int (2011) 0.85
Neuroimaging findings in cryptogenic stroke patients with and without patent foramen ovale. Stroke (2013) 0.84
Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database. J Thorac Oncol (2013) 0.84
Rethinking trial strategies for stroke and patent foramen ovale. Curr Opin Neurol (2010) 0.84
Resources and Capabilities of the Department of Veterans Affairs to Provide Timely and Accessible Care to Veterans. Rand Health Q (2016) 0.83